de Wijs LEM, Fujimoto RFT, Andrinopoulou ER, et al. - In this longitudinal comparative cohort study, researchers examined the effectiveness of dupilumab in patients with atopic dermatitis (AD) in the Netherlands (NL) and Japan (JP) over 80 weeks of treatment. The sample consisted of patients with AD (aged ≥ 13 years in NL, ≥ 15 years in JP) who were treated with dupilumab in daily practice. Statistically significant differences were observed in gender, disease onset, BMI, and therapeutic history between Dutch (n = 208) and Japanese (n = 153) patients. Dupilumab improved Eczema Area and Severity Index scores in Japanese and Dutch patients in a significant, comparable, and sustained manner. However, there were significant differences in the effect on Patient-Reported Outcome Measures between the countries, with Japanese patients having a better outcome.